A critical question indeed. We should answer that. The evaluation of cognitive function may lack sensitivity, specificity and may be insufficiently quantitative. Measurement of a critical biomarker may be as helpful? At the moment, biomarkers are just surrogates of cognitive function, which remains the “real” clinical endpoint. However, with the advance of our knowledge on the pathogenesis of AD along with the development of pathogenesis-specific biomarkers, could biomarkers become the most relevant clinical endpoints?

View all comments by Frederic Calon